GSK (GSK) said Friday that China's National Medical Products Administration has approved Trelegy Ellipta for the treatment of adults with uncontrolled asthma, expanding the drug's use beyond its existing chronic obstructive pulmonary disease indication.
The approval makes Trelegy the only single inhaler triple therapy approved in China for the maintenance treatment of both asthma and COPD, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments